BioFire’s PCR-based point-of-care diagnostic testing provides urgent care clinics with the power of molecular diagnostics in a rapid, easy-to-use system. Onsite infectious disease diagnostics enables urgent care center to provide patients with fast answers, while giving clinicians the information they need to target treatment decisions.
Right now, SARS-CoV-2 is everyone’s top suspect, but many other respiratory bugs can cause similar, overlapping symptoms. Now you can test for SARS-CoV-2 in patients suspected of COVID-19, along with 18 common respiratory pathogens with syndromic testing from BioFire® Respiratory 2.1-EZ (RP2.1-EZ) Panel—now available under an FDA Emergency Use Authorization. Rapid answers on a broad range of pathogens, in about 45 minutes may help improve patient outcomes.